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Summary This article reviews recent literature on phototherapy for pso-
riasis, particularly narrowband UVB. The efficacy, safety, tolerability and 
acceptance of phototherapy are discussed. It focuses in detail on how 
to improve the efficacy and safety in practice by trying to optimize the 
protocols, using combination therapy, monitoring the cumulative dose 
and providing skin cancer surveillance. Careful patient selection, individ-
ualized treatment, long-term therapy plan and complex approach to pa-
tients are the prerequisites for this. Narrowband UVB as the most widely 
used modality of phototherapy for psoriasis has a relatively good efficacy, 
cost, availability and minimal side effects. It represents a valuable treat-
ment, which deserves more utilization and research. Although not so dy-
namic as in systemic drugs, research into phototherapy is ongoing. Even 
in the era of biologics, phototherapy remains an important therapeutic 
modality for psoriasis and other dermatoses and represents an essential 
part of modern dermatological therapy.
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IntroduCtIon
Biologics have temporarily pushed conventional 
systemic antipsoriatic therapy including phototherapy 
aside. However, their longer use in clinical practice 
has revealed that monotherapy is not sufficient in all 
cases. This renewed the interest and research in tradi-
tional systemic therapy not only as potential agents 
to be used in combination with biologics. In order to 
improve the efficacy, tolerance and safety of treatment 
with conventional drugs, it is necessary to additionally 
investigate and incorporate evidence based data into 
guidelines. This also applies to phototherapy. 
Treatment and management of psoriasis requires 
long-term planning. Careful patient selection, indi-
vidualized treatment and complex approach to pa-
tients are very important. Due to its relatively good 
efficacy, costs, availability and minimal side effects, 
phototherapy represents a valuable, but sometimes 
underestimated method, which deserves more utili-
zation and research (1-8).
The history of phototherapy started at the be-
ginning of the last century, when lupus vulgaris was 
treated with UV light by Finsen, consequently hon-
ored with Nobel prize. Nowadays, there are many 
kinds of phototherapeutic modalities and methods 
(Table 1) available, with narrowband UVB (NBUVB) 
and photochemotherapy PUVA being most often 
used for psoriasis (1-8). 
For reaching an optimal effect, phototherapy has 
to be individualized to the phase of disease and to 
the particular patient. This means that the respon-
sible physician must be aware of the mechanism of 
action of various methods and dosage regimens, e.g., 
choice of an optimal method and protocol for the giv-
en disease and its pathophysiology. However, there is 
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a relative lack of literature in comparison to systemic 
drugs. The manufacturers of irradiators do not have 
as much investigative potential as pharmaceutical 
companies, while the methodology and feasibility of 
such studies are considerably difficult.
mEChanISmS of aCtIon
Phototherapy is defined as the therapeutic use of 
light, primarily ultraviolet light. The mechanisms of ac-
tion on the skin are described as photobiological ones. 
At its most basic level, phototherapy represents the ap-
plication of energy to the skin, which means delivery 
of photons to chromophores, absorption of photons 
in chromophores and biologic reaction of the photon 
absorbed energy, generating heat and biochemical ef-
fects in the skin. The most important chromophore for 
photobiological response after UVB is DNA (4,7,9,11).
The antiproliferative (antimitotic, cytotoxic) role 
of UV light was previously thought to be most promi-
nent in phototherapy because of direct DNA dam-
age followed by reduction in DNA, RNA, proteosyn-
thesis and cellular proliferation. Current concepts on 
the mode of action underline the anti-inflammatory 
(immunomodulatory/immunosuppressive) mecha-
nisms, i.e. direct effects on the induction of apop-
tosis (mainly Langerhans cells, T cells) and indirect 
effects via influencing numerous soluble mediators 
(cytokines, prostanoids, neuropeptides, signal trans-
duction molecules, etc.) and cell-surface-associated 
molecules (adhesion molecules, surface receptors, 
etc.) (3,4,8,10). These all contribute to the anti-inflam-
matory effect of UV light (4,9,11,13). In psoriasis, UV 
light inhibits the hyperproliferation of keratinocytes 
and neoangiogenesis (3) and these antiproliferative 
effects are caused both by direct DNA damage and 
indirectly by immune pathways. The mechanism of 
action differs with UVA and UVB, depending on their 
biophysical properties. So, as UVA as long-wave, low-
energy radiation penetrates into the dermis and acts 
on fibroblasts, mastocytes, endothelial cells, dendritic 
cells and dermal T cells. Short-wave, high-energy UVB 
radiation penetrates the epidermis and only partially 
to the upper dermis and acts on keratinocytes, mela-
nocytes, Langerhans cells, mastocytes and epidermal 
T cells. The UVB spectrum has been widely studied. 
It produces a direct and stronger immunosuppres-
sive effect via production of photoproducts and DNA 
damage with consequent cell cycle arrest and late 
apoptosis, effects on soluble and surface structures 
and generally on signal transduction. UVA has an in-
direct and temporary effect via generation of reactive 
oxygen species with early apoptosis (4,6-8,10-14,21). 
The mechanism of immunomodulatory action of 
PUVA has been less well studied (4). 
Both UVA (PUVA) and UVB reduce the expres-
sion of adhesion molecules, especially ICAM-1 (4,6-
8,10,11,13,14), on keratinocytes and Langerhans 
cells. Both spectra cause isomerization of urocanic 
acid from trans to cis form that binds to 5-OH trypt-
amine receptors on mastocytes, dendritic cells and 
Langerhans cells, leading to their functional immu-
nosuppression, blocking deliberation of histamine 
and causing trafficking of mastocytes to lymph 
nodes (13,14). Both UVB and PUVA cause apoptosis 
of keratinocytes, Langerhans cells, dendritic cells, 
macrophages and T cells (4,6-8,11,13). NBUVB espe-
cially reduces Th1 cells and their pro-inflammatory 
cytokines (IL-2, INF gamma and TNF alfa), and down-
regulates the Th17 population via IL-23 axis (15); all 
these play a role in the pathogenesis of psoriasis (16). 
table 1. Modalities and methods of phototherapy
method of phototherapy abbreviation Spectrum (nm)
Natural (solar) phototherapy Heliotherapy UV, visible light, IR
Broadband UVB BB UVB 290-320
Narrowband UVB NB UVB 311-313
Selective UV phototherapy SUP 300-330
Monochromatic excimer light MEL 308
Broadband UVA BB UVA 320-400
Photochemotherapy PUVA PUVA 320-400
Extracorporeal photopheresis ECP 320-400
UVA 1 phototherapy UVA 1 340-400
High energy visible HEV 400-500
Intensive pulse light IPL 515 (-1250)
Photodynamic therapy PDT 600-750






NBUVB stimulates differentiation of regulatory T cells 
via RANK/RANL signaling pathway (receptor activa-
tor of NFkB ligand) on keratinocytes and Langerhans 
cells (17). It is an important mechanism for maintain-
ing self-tolerance and suppressing excessive immune 
responses (18). Consequently, there is an increase in 
anti-inflammatory cytokines, mainly IL-10 (produced 
by keratinocytes, regulatory T cells and macrophages 
with phagocytosed apoptotic cells), alpha-MSH (pro-
duced by keratinocytes) and PGE2 (produced by ke-
ratinocytes and Langerhans cells) and others such as 
TGF beta, IL-4 and CGRP (calcitonin gene related pep-
tide). These are the main mechanisms by which the 
immune reaction in psoriasis is shifted after NBUVB 
from Th1 towards Th2 immune response (4,11-14). 
This broad action of UV light, mainly NBUVB, on 
various molecular targets explains the high efficacy 
of phototherapy. To further investigate the mecha-
nism of action of UV light and immunity of the skin is 
a task for basic research.
IndICatIonS and mEaSurES BEforE 
StartIng PhotothEraPy
In clinical practice, the rules and usage of photo-
therapy at individual dermatologic departments and 
offices differ and there is the need to coordinate or 
standardize protocols and generally to manage pa-
tients on phototherapy in order to reach an optimal 
risk/benefit ratio (protocols, dosimetry, patient infor-
mation, informed consent, combination therapy, can-
cer surveillance, nurse education and training, etc.). 
The most commonly used method of photothera-
py for psoriasis is NBUVB, for example, in Scotland it ac-
counts for 85% (Professor Fergusson’s lecture at EADV 
Congress in Gothenburg, 2010) and in Czech Republic 
81% (19). The main reason is the simplicity of perfor-
mance over PUVA both for patients and for medical 
staff. A significant decrease in the use of PUVA is caused 
not only by the introduction of NBUVB, but also by the 
availability of biologics (3). Nevertheless, before start-
ing phototherapy it is advisable, for quality and safety 
reasons, to undertake the following steps:
-	 indication and proper patient selection 
– motivated, compliant patient
- exclusion of contraindications – history, clin-
ical examination of whole body surface
- assessment of skin and disease reactivity to 
sun, tanning beds or previous phototherapy
- verbal and written education and/or in-
formed consent
- assessment of severity – PASI or BSA as needed
- determination of skin type or minimal ery-
thema dose (MED), choice of phototherapy 
protocol and treatment plan
- appropriate phototherapy record forms and 
documentation (2,3,5,8,14).
Indications for NBUVB are all types of moderate 
to severe psoriasis (severity in area, intensity, course, 
therapeutic response, quality of life), e.g., in cases 
where topical therapy is not sufficient to control the 
disease. On the other hand, it is also indicated in cas-
es where systemic drugs are contraindicated, poorly 
tolerated or not sufficiently effective. NBUVB is con-
sidered to be the first choice of phototherapy meth-
ods in moderate to severe plaque psoriasis because 
of safety reason in comparison to PUVA (2,3,8,20). 
The most suitable indication is psoriasis with thin 
scales and then in children and pregnant women 
(1,6,8,14,20,21). Photochemotherapy PUVA is indi-
cated in thick scale psoriasis, in cases of low clinical 
response or short remission after NBUVB. In chronic 
plaque psoriasis, broadband UVB and SUP are slightly 
less effective than NBUVB and more erythemogenic 
(1-8,20), but they have good effects in eruptive and 
seborrheic forms (38). Further contraindications must 
be ruled out and patient adherence must be con-
firmed. NBUVB is contraindicated in photodermato-
ses and in patients with cutaneous malignancies. Rel-
ative contraindications are skin type I, multiple atypi-
cal nevi, immunosuppression in organ transplant 
patient, epilepsy and physical or psychical obstacles 
like claustrophobia, cardiac insufficiency or inability 
to stand in the UV cabin (1-8,10,14). After assessing 
the indications and contraindications, the physician 
should inform the patient about the benefits as well 
as the side effects and possible risks of phototherapy 
and also provide practical information about the pro-
cess of phototherapy course. 
This basic education should include the use of pro-
tective goggles, shielding genitalia in males, and also 
face and dorsa of hands if not affected, and protection 
of parts with herpes simplex in history and avoiding 
of sunlight exposure during phototherapy course (4-
8,10,14). It is advisable to provide the patient with a 
written information form or even informed consent 
form, where needed. The purpose of this counseling 
and instruction is not only to protect the physician in 
medico-legal aspects, but first of all to reach better 
compliance of patients. They will find here answers 
to frequently asked questions and also advice how to 
avoid the most often errors during phototherapy.
ImProvIng ClInICal ParamEtErS of 
PhotothEraPy
Every drug and treatment is evaluated for param-
eters like efficacy, tolerability, safety, and particularly 
in dermatology also acceptance and convenience. 
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Are there any possibilities to improve these param-
eters in phototherapy?
Acceptance of phototherapy is traditionally very 
good. Although relatively time consuming, patients 
consider phototherapy to be a comfortable and effec-
tive therapeutic method, which is reflected in quite 
good adherence. If not regulated, many patients 
would even like to attend phototherapy for a long 
time. As to the convenience, phototherapy is bound 
to phototherapy departments or centers, so the avail-
ability, geographical accessibility and compliance 
can be sometimes a problem. These factors represent 
the major limitations of UV-based therapy (14). From 
the physician’s point of view, phototherapy needs 
adequate technical, space and staff equipment with 
higher costs and intensive agenda according to com-
pensation records and reimbursement from health 
insurance companies than in ordinary dermatologic 
offices. Our survey in the Czech Republic showed 
good situation concerning availability and accessi-
bility (57 hospital or office based phototherapy cen-
ters), with the exception of border regions (19). In our 
country, phototherapy is covered by health insurance 
companies. In case of poor accessibility, home pho-
totherapy can be useful in motivated and equipped 
patients under the physician’s monitoring (regular 
visits, clinical follow up). United States experience 
shows a high level of compliance, improved quality of 
life, and lower direct and indirect cost (time and sal-
ary lost, transport costs, etc.) in comparison to other 
treatments for severe psoriasis, including methotrex-
ate, PUVA, acitretin, and biologics (23,24). Generally, 
both UVB and PUVA therapies have been shown to 
be 4-6 times more cost-effective as compared with 
biologics (22). Of course, home phototherapy is not a 
solution for all patients, both for financial (purchasing 
the device) and medical reasons (overuse, underuse, 
inappropriate use) (23,24). The tolerability of NBUVB 
is good with occasional erythema (UV dermatitis) and 
xerosis as the almost single side effects that can be 
well managed (1-11). However, the main issues are ef-
ficacy and safety. 
SafEty
Safety of phototherapy is an ongoing topic. There 
are more than fifty years of clinical experience with 
phototherapy depending on the modality used 
(2,4,6). Although UV light generally has a carcinogen-
ic potential, till now there are no clinically relevant 
human data on skin cancer with NBUVB in psoriasis, 
e.g., data available on human use are inconclusive for 
a significant risk (2,3,6,10,25,26). Another situation is 
in photochemotherapy PUVA because in high doses 
there is a substantially increased risk of squamous cell 
carcinoma and melanoma and a small increase in the 
risk of basal cell carcinoma (2,3,5,14,25,26). However, 
with higher cumulative doses the potential risks must 
be taken into account also in NBUVB (20). In PUVA, 
there is a recommendation for the whole life maximal 
cumulative dose of 1000 J/cm2 (or 200-300 sessions) 
(2,3,5,20). For NBUVB, the limit is not given as a cumu-
lative dose, but according to current consensus, the 
cumulative number of 450-500 sessions should not 
be exceeded (20). For improving safety it is necessary 
to encourage all physicians to calculate it and not to 
regulate phototherapy by limiting it to “two courses a 
year”, etc. This ceiling must be taken as relative and in-
dividual (27), also according to the fact that in severe 
psoriasis only stronger immunosuppressive drugs 
(methotrexate, cyclosporine A) are alternatives to 
phototherapy (6,20,27). It is advisable to identify pa-
tients whose cumulative dose has exceeded the ceil-
ing as the risk-takers and to follow them more care-
fully. Some authors recommend to record cumulative 
doses of single courses not only in medical forms, but 
in a kind of patient UV passport (5,6). Nevertheless, 
patients with repeated phototherapy (>200-250 ses-
sions) should undergo dermato-oncologic screening 
at least once a year (10,14). 
On assessing the risks of phototherapy, it is nec-
essary not to mix them up with the risks of tanning 
beds and sun-tanning. There are fundamental differ-
ences between them. The latter exposure to UV light 
is medically uncontrolled, most people are the risk 
phototype I or II, do not use any sunscreens, and their 
behavior is often of addictive type (28), so the number 
of visits/exposures is not limited. On the other hand, 
phototherapy is justified by its benefits for the patient, 
resulting in reduction or clearance of the disease and 
its stabilization. In comparison with systemic antipso-
riatic drugs, the risk/benefit profile of phototherapy is 
very good because it generally lacks the properties of 
systemic immunosuppressive drugs. 
Besides shielding unaffected areas, regular pa-
tient monitoring during phototherapy by the physi-
cian, monitoring of cumulative doses and skin cancer 
monitoring, there is also a technical possibility how to 
improve the safety, i.e. with focused, targeted photo-
therapy. Refinements of the delivery systems for UVB 
are beneficial in reducing the unnecessary exposure of 
uninvolved skin (29). However, current devices are only 
suitable for localized psoriasis or for a low number of 
lesions because of small irradiation area, thus requir-
ing unacceptably long time in disseminated psoriasis. 
Computerized, robotized whole body device with high 
output that would, after scanning the affected area, se-
lectively irradiate only the involved skin in short pulses, 
is the perspective. Yet, there is the question of cost-ef-





The efficacy of phototherapy can reach clearance 
in 63%-80% of patients with a course of NBUVB (20) 
and generally phototherapy can achieve PASI 75 on 
average in 75% of patients after 4-6 weeks (2,4,6). This 
is very good efficacy in comparison with systemic 
drugs and even with biologics. Recent analysis (30) 
showed superior effects of PUVA even over certain 
biologics (adalimumab, alefacept, efalizumab, etan-
ercept, ustekinumab). An optimal phototherapy pro-
tocol should lead to complete clearance or marked 
improvement (PASI >75) with a minimum number of 
sessions, a low cumulative dose, and with the least 
possible acute and chronic side effects (6,10,20). This is 
a difficult task because phototherapy and its dosages, 
although working with exact physical variables, does 
not have a direct dose-effect relationship, and toler-
ance is the deciding and limiting factor. So, a higher 
dose does not always mean a higher effect. Photobio-
logical effects are more similar to those of biologics 
or topical immunomodulators. Clinical response is 
here also very individual depending on genetic het-
erogeneity, i.e. immune, metabolic and pharmacoge-
nomics properties. Because of different (heterogenic) 
immune background of the disease, people with the 
same appearance of psoriasis (phenotype) may have 
different therapeutic responses to the same treat-
ment. Metabolic and pharmacogenomic heterogene-
ity plays a role mainly in systemic drugs for psoriasis 
(31), but also in phototherapy there are genetic dis-
positions for tolerance and positive reactions to UV 
(biomarkers, e.g., polymorphism of vitamin D recep-
tor) that could in the future be used for prediction of 
therapeutic response in individual patients (32).
Thus, in order to enhance the effect of treatment, 
physicians do not just need to actualize the knowl-
edge by studying professional literature, but also 
from self-learning based on their own experience. 
However, experience with a relatively small number 
of patients is usually not enough to draw general 
conclusions. To get statistically significant data, large 
numbers of patients treated and assessed by compa-
rable methodology are needed. There is an initiative 
from phototherapy centers in Scotland in this sense, 
called Photonet (Scottish Managed Clinical Network 
for Phototherapy), which could enable analysis for 
detecting optimal protocols from the efficacy and 
safety point of view (20,33). Professor Fergusson 
and co-workers in Dundee created this registry in 
2002 in a bid to standardize phototherapy treatment 
throughout Scotland. All centers send their data in 
structured forms (patient demography, protocol, ef-
ficacy and tolerance data) to this registry. So they ob-
tain data from large patient samples and due to the 
same methodology, their stratified analysis is pow-
ered enough to draw conclusions concerning optimal 
regimens and protocols. It also provides information 
forum for both healthcare professionals and patients. 
They can “discuss clinical issues, collaborate and share 
skills and information” (www.photonet.scot.nhs.uk). 
Nevertheless, as mentioned further, there are differ-
ences between study populations and results cannot 
be simply extrapolated to another population (33). 
Therefore, it would be optimal to create regional or 
national registries to obtain relevant data.
There are two possible ways to improve efficacy; 
first, to optimize protocols and/or to combine photo-
therapy with topical or systemic treatments. Never-
theless, to ensure the success of every treatment, the 
prerequisites are knowledge and skills, as well as the 
approach by physicians. 
oPtImIzIng thE ProtoColS
The protocol represents a treatment scheme, a 
schedule including the following parameters: start-
ing dose, increments, frequency of increments, 
maximal single dose, frequency of sessions per week, 
total duration of phototherapy course and/or total 
number of sessions (6,20,34). Are there any reserves 
to improve or optimize the protocols? According to 
textbooks, the initial dose of NBUVB phototherapy is 
calculated on the basis of MED or skin type (photo-
type). The starting dose is recommended as 70% of 
MED (2-7,10,14,34), in US protocols only 50% of MED 
(5,8,20,29). In skin type regimen the initial dose is 
given according to the recommended dose ladder; 
e.g., in Europe, for phototype I=200, II=300, III=500, 
IV=600 mJ/cm2 (2,5,7), or even on the basis of individ-
ual experience. In US protocols, the dose is by about 
one half lower (14,34). In many centers, according to 
data from the literature and from our Czech survey 
(10,14), MED is not determined. There is a concern of 
underestimating the initial dose with consequences 
like prolongation of the effect onset and therapy 
(10). According to a Scottish study in phototypes I-III, 
there were no significant differences in the efficacy of 
NBUVB therapy (increments by 20%) between three 
starting doses: group A, fixed dose; group B, 70% 
MED; and group C, 50% MED (35). So, what is the 
conclusion? These authors wisely state in the end of 
their article: “in populations with a broader range of 
erythemal sensitivity” (than in Scotland), “the MED 
based starting dose could have an important impact 
on treatment effectiveness” (35). 
Another key issue of debate is dose escalation, 
which depends on erythema response. The dose may 




of 3 times per week frequency, and every other ses-
sion when given 5 times a week (7). In MED based 
protocol, the percentage increments are on average 
by 30% of the last dose, an in case of minimal ery-
thema by 20% (2,5,6). There are differences in proto-
col increments between departments probably due 
to the spectrum of patient population; Europe with 
20%-40% increase versus United States with a lower 
increase by 10%-15% (3,8,14,34). This may be also in-
fluenced by local experience, tradition, more patients 
with lower phototypes in their population and may-
be by the fear from potential complaints in patients 
with burning reaction. Fixed increments are used in 
skin type based protocols, mainly in the US, in the 
range of 0.03-0.15 J/cm2 (3,8,34) that evolved from 
a low increment protocol for BBUVB. There is a pre-
sumption that the efficacy can be enhanced by larger 
increments because the erythemogenicity of NBUVB 
is lower, about one-fourth that of BBUVB (36). To the 
best of my knowledge, there are no concrete refer-
ences about fixed increment protocols for NBUVB in 
European literature. In my opinion, adherent patients 
of skin type III-IV tolerate 0.1-0.2 J/cm2 increments on 
an average and the onset of effect is faster (19,37). 
This increment represents approximately 20% of 
fixed starting dose for phototype III and 30% of fixed 
starting dose for phototype IV. This correlates with 
the percentage increments based on MED in Euro-
pean protocols mentioned above. Also, other data 
on this topic are of anecdotal or local character (for 
example, the internet website www.psoriasis-inter-
national.org, supervised by professor Louis Duber-
tret, offers schemes with fixed increments of 0.1-0.3 
J/cm2) and need to be confirmed by further clinical 
investigation. Proper dosimetry, calibration and suf-
ficient number of patients are necessary to avoid bias 
and incorrect conclusions.
In daily practice, it is a challenge for physicians to 
choose the proper regimen (36,38,39) because the 
percentage increments regimen (exponential curve, 
Fig. 1), although recommended in the literature, 
means that it is not easy for a physician or nurse to 
calculate the individual dose before every session if 
a change is needed due to actual tolerance, efficacy 
and patient compliance (e.g., irregular attendance). 
This regimen has worse flexibility and lucidity. Fixed 
increments regimens (linear curve) are easy to follow 
by a nurse, and there is good flexibility. When work-
ing with a maximum single dose 1.5 J/cm2 , under 
good patient tolerance, there is only a small or no dif-
ference in time to reach it and also in the cumulative 
dose between fixed increments by 0.2 J/cm2 and per-
centage increments by 40% (Fig. 1). However, if work-
ing with small increments, e.g., by 20%, the maximum 
single dose 1.5 J/cm2 is reached about one or two 
weeks later and a slower onset of effect, prolongation 
of therapy and possible increase of cumulative dose 
to clearing can occur. The high-dose regimen (40%) 
results in fewer sessions with better long-term effi-
cacy, but requires flexible dose adjustment in the sec-
ond week, e.g., at the beginning, to prevent erythema 
(38). In Scotland, there is a preference of low-dose 
regimen, where less frequent sunburn-like erythema 
episodes occur (39). The optimal NBUVB photothera-
py regimens for psoriasis may vary according to the 
population and settings; therefore, they call for future 
randomized studies for a given population with suf-
ficient methodological records on safety and efficacy 
to justify the high-dose regimen (33). 
So, which regimen to choose? In the literature, 
there is no universal answer. If there is well-trained 
staff, an educated and adherent patient, and also if 
the physician can regularly monitor the patient at 
least once a week and can flexibly change the dose 
according to reactivity and tolerance, the high dose 
regimen should not induce more burning reactions 
than the low dose one. Should the fixed or percent-
age increments be used? The fixed increments regi-
men seems to be more suitable and convenient for an 
“average” patient of skin type III-IV (and also for home 
phototherapy). Yet, individualization is needed in ev-
ery patient. Thus, for example in patients with dispo-
sition to erythematous reaction at the beginning of 
photototherapy, the percentage increments regimen 
would be more suitable because the increments are 
slightly slower than in fixed increments regimen.
	The maximum single dose should not exceed 3 
J/cm2 (8,14), but it is advisable, if efficacy allows it, to 
work for safety reasons with 1.5 J/cm2 and 2 J/cm2. 
The often discussed frequency of sessions (2-5/week) 
is in fact a matter of dose, e.g., it indirectly correlates 
with the so-called reciprocity rule (relation of intensi-
ty and exposure time to the dose). So, in devices with 
low intensity, e.g., low dose regimen, the frequency 
should be higher, while in cabins with usual output 
(10 mW/cm2) attendance three times a week is usu-
ally sufficient. The frequency of five times a week in 
devices with usual output is time consuming for the 
patient, does not shorten total duration to clearance 
and increases total cumulative dose (10,40). Lower 
frequency, e.g., two times a week, requires longer 
duration of treatment (1.5 times longer) and needs 
more sessions in comparison to three times a week 
(41). Therefore, current recommendations work with 
the frequency of three times a week, as it is optimal 
from the aspect of patient time (2,4,5,7). 
In this context, there is an interesting field for fur-
ther investigation. It is known that in devices with 
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very low or very high intensity, the reciprocity rule 
does not hold true. In psoriasis, devices with very high 
intensity, e.g., 308 nm UVB excimer lasers or non-laser 
monochromatic excimer light (MEL) devices work-
ing with supra-erythemogenic doses, can reach bet-
ter clinical response by the same cumulative dose in 
comparison with usual NBUVB (Philips TL 01), or in 
other words, the same effect can be achieved with a 
fewer number of treatments and a lower cumulative 
dose (2,29,42). 
Another field for clinical research is to further in-
vestigate topical photochemotherapy with NBUVB in 
the form of cream or solution (no references about 
bath delivery available, rare about peroral). This PN-
BUVB is less well-established than PUVA (20), most 
references coming from India (10,43). What are the 
advantages of this combination? Psoralens in topical 
form are safer and more comfortable than the system-
ic route. Photosensitization is not as strong as with 
UVA, but still there is an increase by about 3.5 in NBU-
VB. So, it enables lower doses of UVB, thus improving 
the safety and topical PUVB is generally considered 
to be safer than PUVA at long term. There are fewer 
references comparing the efficacy, some of them 
documenting higher efficacy and lower cumulative 
dose than NBUVB alone, without an increase in side 
effects (10,43). Interestingly, psoralens alone without 
UV light bind to the receptors for epidermal growth 
factor, followed by a decrease in epidermal prolifera-
tion (14). They also have marked prooxidative prop-
erties (enhancing the generation of reactive oxygen 
species and free radicals) on cell surface membranes, 
so they can act independently of UV (44). In practice, 
PNBUVB is suitable especially for recalcitrant localized 
forms, e.g., palmoplantar psoriasis (10,44).
Cessation of phototherapy depends on clinical 
response. It is usually continued until complete clear-
ance is achieved or no further improvement can be 
expected. This takes 2-3 months or 25-35 sessions on 
an average. Maintenance phototherapy with NBUVB 
in psoriasis is a matter of debate, there are no suffi-
cient data to support it (2-6,20). Safety concerns are 
speaking against maintenance therapy for common 
use (2,4,20). Also practical aspects play a role, as it is 
time consuming and expensive (1,4). Thus, nowadays 
NBUVB and generally phototherapy is considered a 
treatment as induction therapy for psoriasis, but not 
recommended as maintenance therapy (2).
ComBInatIon thEraPy
Another way to increase clinical response (addi-
tive or synergistic effect) and also partially the safety 
of phototherapy is to combine it, first of all with topi-
cal therapy (2-4,6,10,20,29). However, before thinking 
about adding a combination to phototherapy, it is 
advisable to search for ways to improve photother-
apy itself (besides looking for adherence, triggering 
factors, etc.) because it is simpler for both the patient 
figure 1. Narrowband UVB dose increments to 1.5 J/cm2.
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and the physician/phototherapy center (10). Com-
bination with topical therapy requires more space, 
technical and staff equipment, it is laborious, takes 
more time, and generally the costs are higher. On the 
other hand, combination therapy may reduce the cu-
mulative NBUVB dose and the potential carcinogenic 
risk and should not be dismissed without further 
studies (1,20).
ComBInatIonS wIth toPICal drugS
Historically, Goeckermann introduced a combina-
tion of BBUVB with coal tar in 1925 and later on Ingram 
with anthralin (dithranol). NBUVB can be combined 
with both, including all current topicals (1,4,6,29). The 
most positive references are about dithranol for inpa-
tient and calcipotriol for outpatient settings (4,10,29). 
Combination with calcipotriol is the most evidence 
based one, even in the recent German and American 
guidelines from 2011 (2,3).
A modified Goeckerman method with NBUVB is 
based on photosensitive and antimitotic properties 
of coal tar, however, tar smells, stains and has irri-
tative and carcinogenic properties. Dithranol with 
NBUVB has no photosensitivity potential and has a 
higher efficacy than tar. However, it bears a risk of ir-
ritation, so that not all patients tolerate it. There is an-
other possible combination of NBUVB, namely with 
ichthyol. It is a sulfonated shale oil (ammonium bitu-
monosulfonate) with anti-inflammatory, antiseptic 
and antipruritic properties. It was originally used for 
treating wounds and later for treating some dermato-
ses, especially eczema and rosacea. Ichthyol has been 
proved not only by historical experience, but also by 
growing evidence based studies (45). The advantage 
of ichthyol over tar, dithranol and even calcipotriol is 
almost no irritative potential and no phototoxic or 
carcinogenic potential. Ichthyol also has antiprolifer-
ative and UVB erythema reducing effects that might 
play a role in psoriasis treatment (46). Furthermore, 
it can be easily washed off with water and has an ad-
vantageous price. Ichthyol still represents a valuable 
topical (good benefit/risk/cost profile) because, ex-
cept for corticosteroids and topical immunomodula-
tors, there are no other anti-inflammatory topicals in 
dermatology available. In the Czech Republic, some 
centers also use it for treating psoriasis. I have been 
using ichthyol in combination with NBUVB for many 
years and conducted a study in severe psoriasis pa-
tients, where 100% short contact ichthyol and NBUVB 
were used. The results confirmed very good efficacy 
(after 20 sessions: mean reduction in PASI = 72%, 
mean improvement in DLQI=53%), tolerability, safety 
and acceptance. It is suitable especially for psoriasis 
patients with irritable or potentially irritable terrain, 
e.g., guttate, seborrheic or unstable psoriasis, in chil-
dren and in all cases where dithranol or tar are not 
tolerated or cannot be used (37).
Treatment with topical corticosteroids during 
phototherapy is not a true combination therapy, 
but a concomitant therapy in the beginning of pho-
totherapy. There is a trend not to use them during 
phototherapy (“corticosteroid holidays”), but it does 
not mean they are prohibited (2,3). In practice, they 
should be slowly tapered and ceased according to 
the onset of clinical response to phototherapy (29).
There are considerable differences in using emol-
lients during phototherapy. According to variations 
in UV transmission and UV blocking potential in some 
of them, it is advisable to use them after rather than 
before phototherapy session (47). For better trans-
mission, a short warm water shower (48) or the ap-
plication of mineral oil can be used before treatment 
(8,10). 
ComBInatIonS wIth BathS
In Germany, balneophototherapy is quite popu-
lar, mainly with salt baths (2,4,20) in asynchronous 
or synchronous way (49) with NBUVB, SUP or BBUVB. 
Some studies documented higher efficacy than pho-
totherapy alone (49,50), but the cumulative dose was 
not reduced, there is no standardization in salt con-
centration and mineral content, and particularly the 
cost-effectiveness has not been advantageous so far 
(48,50). 
ComBInatIonS wIth SyStEmIC drugS
Combination of NBUVB with systemic drugs is rep-
resented mainly by retinoids, e.g., acitretin (reNBUVB, 
rePUVA), because it has no immunosuppressive prop-
erties (2,3,4,6,8,29,51). This combination accelerates 
the onset of clinical response, enables reduction of 
acitretin dose (25-10 mg/day) and moderately also 
the number of sessions or cumulative dose, by 20% 
on an average. It is advisable to start acitretin one or 
two weeks before phototherapy, the dose should be 
increased cautiously because of epidermal thinning 
caused by acitretin, usually by 20%-30% (3,14). Com-
bination with retinoids is safe, effective and may even 
help reduce cancer risk (4). Other antipsoriatic drugs 
such as methotrexate, biologics, e.g., etanercept, do 
not represent a true combination to increase the effi-
cacy of phototherapy. Phototherapy is here a tempo-
rary adjunctive method for increasing the efficacy of 
these systemic drugs in case of clinical response loss 
or flare. Of course, in such combinations the cumula-
tive dose of UVB is significantly lower. They are used 




(3,6,10,52,53), especially in smokers and obese pa-
tients, who are already at a higher risk (52). There are 
increasing references about the use of methotrexate 
in a sequential way, e.g., starting three weeks before 
phototherapy in a dosage of 15 mg/week and lead-
ing to significantly shorter time to clearance (3,29,54). 
Concomitant combination with cyclosporin A is 
strictly contraindicated in PUVA (2-7), in NBUVB it is 
not recommended and can only be used exception-
ally and very cautiously as short-term course on resis-
tant plaques (5,29).
ConCluSIonS
Even in the 21st century, phototherapy represents 
an important therapeutic modality for psoriasis and 
other dermatoses due to its good efficacy, safety, pa-
tient compliance profile and cost/benefit ratio. Even 
in the era of biologics, phototherapy remains an im-
portant therapeutic tool that cannot be replaced by 
any other current systemic therapy. Although not as 
dynamic as in systemic drugs, research to improve 
the efficacy and safety of phototherapy is going on.
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